
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="2" face="Times New Roman"><img width="208" height="26" src="g153251kgimage002.gif"></font></p>

<p style="border:none;line-height:3.0pt;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p style="line-height:6.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:9.0pt;letter-spacing:.1pt;">128
Sidney Street, Cambridge, MA 02139-4239&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TEL:
(617) 995-2500&#160;&#160; FAX: (617) 995-2510</font></p>

<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contacts</font></u></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="91%" style="border-collapse:collapse;margin-left:.5in;width:91.5%;">
 <tr>
  <td width="287" valign="top" style="padding:0in 0in 0in 0in;width:215.0pt;">
  <h1 style="font-weight:normal;margin:3.0pt 0in .0001pt;page-break-after:avoid;text-align:justify;text-decoration:underline;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Investors:</font></u></h1>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Carol Hausner</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive Director,
  Investor Relations<br>
  and Corporate Communications</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: (617) 995-2500</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">info@immunogen.com</font></p>
  </td>
  <td width="267" valign="top" style="padding:0in 0in 0in 0in;width:200.0pt;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Media:</font></u></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tony Loke</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rx Communications Group,
  LLC</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: (917) 322-2164</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">tloke@rxir.com</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></u></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:6.0pt 0in 4.0pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ImmunoGen, Inc. Announces that
Centocor Has Licensed</font></b></p>

<p align="center" style="margin:6.0pt 0in 12.0pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certain Rights to ImmunoGen&#146;s
Tumor-Activated Prodrug Technology</font></b></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CAMBRIDGE,
MA December 28, 2004</font></b><font size="2" style="font-size:10.0pt;"> &#151; ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology
company that develops targeted anticancer products, today announced that
Centocor has licensed certain exclusive rights to </font><font size="2" style="font-size:10.0pt;">ImmunoGen&#146;s Tumor-Activated Prodrug (TAP) technology.
Centocor is a wholly-owned subsidiary of Johnson &amp; Johnson and</font><font size="2" style="font-size:10.0pt;"> a leader in
antibody-based therapeutics</font><font size="2" style="font-size:10.0pt;">.</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the agreement, Centocor will receive exclusive
worldwide rights to develop and commercialize anticancer therapeutics that
comprise a Centocor antibody that binds to an undisclosed cancer target and a
maytansinoid cell-killing agent developed by ImmunoGen. ImmunoGen&#146;s
cell-killing agents are designed specifically for antibody-directed delivery to
cancer cells.</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Centocor will be responsible for the research, development, manufacturing,
and marketing of any products resulting from the license. ImmunoGen will
receive from Centocor an upfront payment of $1 million, milestone payments that
potentially total $42.5 million, and royalties on the sales of any resultant
product. ImmunoGen also will receive financial compensation for product
development research done on behalf of Centocor and for the production of
preclinical and early clinical materials for Centocor.</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mitchel Sayare, PhD, ImmunoGen Chairman and CEO, said, &#147;We are
delighted to enter into this collaboration with Centocor, a recognized leader
in antibody-based therapeutics. Centocor is the seventh major company that has
licensed the right to use our TAP technology, and we now have collaborations
with the three leaders in the development and commercialization of
antibody-based products: Centocor, Biogen Idec, and Genentech. These licenses
expand the number of TAP compounds in development, and help us fund our own
product programs.&#148;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-more-</font></p>

<div align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\rcheney\04-15325-1\task263022\15325-1-kg.htm',USER='rcheney',CD='Dec 27 11:43 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ImmunoGen&#146;s TAP technology is designed to provide cancer-targeting
engineered antibodies with significant clinical activity. ImmunoGen attaches a
potent cell-killing agent to the antibody as a payload. The antibody serves to
carry the payload specifically to cancer cells, and the payload serves to kill
the cancer cells.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About ImmunoGen, Inc.</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ImmunoGen, Inc. develops
targeted anticancer biopharmaceuticals. The Company&#146;s proprietary TAP
technology uses cancer-targeting engineered antibodies to deliver a potent
cell-killing agent specifically to cancer cells. ImmunoGen is advancing its
wholly-owned TAP compounds, huN901-DM1 and huC242-DM4. Aventis, Genentech,
Biogen Idec, Boehringer Ingelheim, Centocor, Millennium Pharmaceuticals, Inc.,
and Abgenix have licensed the right to develop or test TAP compounds to
specific targets; ImmunoGen also has a broader collaboration with Aventis, part
of the sanofi-aventis Group. For additional information on ImmunoGen, please
visit www.immunogen.com.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This press release includes forward-looking statements based
on management&#146;s current expectations. For these statements, ImmunoGen claims
the protection of the safe harbor for forward-looking statements provided by
the Private Securities Litigation Reform Act of 1995. Various factors could
cause the Company&#146;s actual results to differ materially from those discussed or
implied in the forward-looking statements and you are cautioned not to place
undue reliance on these forward-looking statements, which are current only as
of the date of this release. Factors that could cause future results to differ
materially from such expectations include, but are not limited to: the outcome
of the Company&#146;s research and clinical development processes, including the
anticipated clinical advancement of huC242-DM4 and huN901-DM1; the outcome of
the Company&#146;s collaboration partners&#146; research and clinical development
processes, including the anticipated clinical advancement of partner compounds;
the difficulties inherent in the development of pharmaceuticals, including
uncertainties as to the timing, expense and results of preclinical studies and
clinical trials; the Company&#146;s dependence upon existing and potential
collaborative partners, and the outcome of the clinical testing of TAP
compounds being developed by the Company&#146;s existing partners; uncertainty as to
whether the Company&#146;s potential products or those of the Company&#146;s
collaborators will succeed in entering human clinical trials and uncertainty as
to the results of such trial; the risk that the Company and/or its
collaborators may not be able to obtain regulatory approvals necessary to
commercialize their product candidates; the potential development by
competitors of competing products and technologies; uncertainty whether the
Company&#146;s TAP technology will produce safe, effective and commercially viable
products; and other factors more fully described in ImmunoGen&#146;s Annual Report
on Form 10-K for the fiscal year ended June 30, 2004 and other reports filed
with the Securities and Exchange Commission.</font></i></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"># # #</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\rcheney\04-15325-1\task263022\15325-1-kg.htm',USER='rcheney',CD='Dec 27 11:43 2004' -->


</body>

</html>

